News & Updates

Long-acting CAB+RPV injections feasible in teens with HIV

06 Aug 2024 by

Virally suppressed adolescents living with HIV-1 who switched from daily oral to long-acting (LA) injectable cabotegravir (CAB) plus rilpivirine (RPV) every 8 weeks show an acceptable safety profile, with pharmacokinetics similar to adults, according to the week-48 results of the IMPAACT 2017 study.

Long-acting CAB+RPV injections feasible in teens with HIV

06 Aug 2024

Statin overuse in acute cerebral ischaemia linked to thousands of AEs per year

06 Aug 2024

More than one-fifth of patients with acute cerebral ischaemia (ACI) appear to be receiving statins unnecessarily, which has the potential to cause higher than 5,600 adverse events (AEs) each year, including diabetes, myopathy, and eye disease, according to the results of a meta-analysis.

Statin overuse in acute cerebral ischaemia linked to thousands of AEs per year

06 Aug 2024

Original New Drug Application Approvals by US FDA (16-31 July 2024)

06 Aug 2024

New drug applications approved by US FDA as of 16-31 July 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 July 2024)

06 Aug 2024

Less risk, same benefit with relugolix combination vs monotherapy for endometriosis-related pain

05 Aug 2024 by

In the treatment of women with endometriosis-associated pain, relugolix combination has a risk-benefit profile that is more favourable than that of monotherapy, due to the latter contributing to increased vasomotor symptoms and substantial bone mineral density (BMD) loss, as shown in a study.

Less risk, same benefit with relugolix combination vs monotherapy for endometriosis-related pain

05 Aug 2024

How viable is a self-administered injection in adults with HIV?

05 Aug 2024 by

A substudy of the phase III FLAIR study has found comparable efficacy and pharmacokinetics for cabotegravir (CAB) plus rilpivirine (RPV) via subcutaneous (SC) administration relative to those via intramuscular (IM) gluteal injections among virally suppressed individuals living with HIV-1.

How viable is a self-administered injection in adults with HIV?

05 Aug 2024

KEYNOTE-585 final analysis support perioperative pembrolizumab-chemo for G/GEJ cancer

05 Aug 2024 by

Perioperative pembrolizumab plus chemotherapy confers survival benefit in individuals with locally advanced gastric and gastroesophageal junction (G/GEJ) cancer in the final analysis of the phase III KEYNOTE-585 trial.

KEYNOTE-585 final analysis support perioperative pembrolizumab-chemo for G/GEJ cancer

05 Aug 2024

Low-dose aspirin exerts no effect on progression of age-related hearing loss

05 Aug 2024

Daily intake of 100-mg aspirin over 3 years does not appear to limit the progression of age-related hearing loss, according to a secondary analysis of the ASPREE study.

Low-dose aspirin exerts no effect on progression of age-related hearing loss

05 Aug 2024

IVIG plus prednisolone does not help improve chances of pregnancy

04 Aug 2024 by

The use of intravenous immunoglobulin (IVIG) plus prednisolone does not appear to increase conception rates among women with recurrent pregnancy loss who are undergoing assisted reproductive technology (ART), according to a study.

IVIG plus prednisolone does not help improve chances of pregnancy

04 Aug 2024

Bintrafusp alfa demonstrates therapeutic potential in cervical cancer

04 Aug 2024

Bintrafusp alfa, an investigational first-in-class bifunctional fusion protein, appears to induce response in patients with recurrent or metastatic cervical cancer, according to a phase II study.

Bintrafusp alfa demonstrates therapeutic potential in cervical cancer

04 Aug 2024

Doubled etonogestrel dose linked to enhanced contraception in HIV-positive women on efavirenz

03 Aug 2024

Placement of two etonogestrel implants instead of one appears to suppress ovulation and increase plasma etonogestrel exposure, thereby increasing contraceptive effectiveness in HIV-positive women on efavirenz-based antiretroviral therapy (ART).

Doubled etonogestrel dose linked to enhanced contraception in HIV-positive women on efavirenz

03 Aug 2024

News & Updates

Filter by Specialty:

Specialty:

Long-acting CAB+RPV injections feasible in teens with HIV

Long-acting CAB+RPV injections feasible in teens with HIV

Statin overuse in acute cerebral ischaemia linked to thousands of AEs per year

Statin overuse in acute cerebral ischaemia linked to thousands of AEs per year

Original New Drug Application Approvals by US FDA (16-31 July 2024)

Original New Drug Application Approvals by US FDA (16-31 July 2024)

Less risk, same benefit with relugolix combination vs monotherapy for endometriosis-related pain

Less risk, same benefit with relugolix combination vs monotherapy for endometriosis-related pain

How viable is a self-administered injection in adults with HIV?

How viable is a self-administered injection in adults with HIV?

KEYNOTE-585 final analysis support perioperative pembrolizumab-chemo for G/GEJ cancer

KEYNOTE-585 final analysis support perioperative pembrolizumab-chemo for G/GEJ cancer

Low-dose aspirin exerts no effect on progression of age-related hearing loss

Low-dose aspirin exerts no effect on progression of age-related hearing loss

IVIG plus prednisolone does not help improve chances of pregnancy

IVIG plus prednisolone does not help improve chances of pregnancy

Bintrafusp alfa demonstrates therapeutic potential in cervical cancer

Bintrafusp alfa demonstrates therapeutic potential in cervical cancer

Doubled etonogestrel dose linked to enhanced contraception in HIV-positive women on efavirenz

Doubled etonogestrel dose linked to enhanced contraception in HIV-positive women on efavirenz